Pre-emption Rule Delays Safety-related Label Changes, Waxman Charges
Executive Summary
An FDA rule that requires the agency to approve labeling changes before they can be made has delayed the addition of safety information to at least two products, according to a report from Rep. Henry Waxman, D-Calif
You may also be interested in...
OTC Decisions In April: Naproxen CV Risk Warning, Sun US Line Rises, Perrigo Omeprazole 'Melt In Mouth' Flag
The first US approvals for adding cardiovascular risk warnings to OTC naproxenb products were for the Aleve line of multiple formulations and delivery formats and in multiple container sizes and Biopharma and Catalent 220-mg capsules. Sun Pharma extends into expectorant/allergy and diarrhea remedy spaces in US OTC market.
Who’s Next In Congressional Hot Seat? Pharma Industry Could Replace FDA
Congress will not keep up its intense scrutiny of FDA when President-elect Barack Obama takes office, drug and device lawyers predict. Instead, Capitol Hill will shift its attention to pharmaceutical company practices
Who’s Next In Congressional Hot Seat? Pharma Industry Could Replace FDA
Congress will not keep up its intense scrutiny of FDA when President-elect Barack Obama takes office, drug and device lawyers predict. Instead, Capitol Hill will shift its attention to pharmaceutical company practices